vTv Therapeutics Inc - Class A
Research vTv Therapeutics Inc - Class A (VTVT) on Bullrun: market cap USD 133.56M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVTVT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 133.56M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 13.05M
- Free cash flow-USD 11.44M
Valuation Snapshot
latest market cap is USD 133.56M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 26.97M | -USD 25.26M | n/a | -3.35 | USD 88.93M | USD 0 | USD 64.44M |
| FY2024 | USD 1.02M | -USD 18.46M | -USD 25.31M | n/a | -3.41 | USD 36.75M | USD 169.00K | USD 12.20M |
| FY2023 | USD 0 | -USD 20.25M | -USD 19.08M | n/a | -17.75 | USD 9.45M | USD 529.00K | -USD 24.68M |
| FY2022 | USD 2.02M | -USD 19.16M | -USD 16.04M | n/a | n/a | USD 12.13M | USD 587.00K | -USD 10.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 133.56M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 157.51M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 36.08M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 23.43M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 54.02M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 66.61M | n/a | n/a | n/a |
About vTv Therapeutics Inc - Class A
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is vTv Therapeutics Inc - Class A's market cap?
vTv Therapeutics Inc - Class A's market capitalization is USD 133.56M.
What does vTv Therapeutics Inc - Class A do?
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd.